Treatment of chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Treatment of chronic myelogenous leukemia

Published:2016-02-01 Issue:3 Volume:73 Page:113-120
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Kujak Christine¹,Kolesar Jill M.²

Affiliation:

1. University of Wisconsin–Madison School of Pharmacy, Madison, WI

2. University of Wisconsin–Madison School of Pharmacy and University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/73/3/113/28335604/ajhp0113.pdf

Reference54 articles.

1. National Comprehensive Cancer Network. NCCN guidelines for patients: chronic myelogenous leukemia. www.nccn.org/patients/guidelines/cml/index.html#8 (accessed 2014 Jul 22).

2. American Cancer Society. Cancer facts and figures, 2015. www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index (accessed 2015 Mar 7).

3. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos;Tefferi;Cancer,2009

4. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013;Baccarani;Blood,2013

5. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate;Dwyer;Blood,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence;Immunity, Inflammation and Disease;2022-05-11

2. Mutations in the BCR‑ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis;Oncology Letters;2020-05-20

3. The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data;European Journal of Haematology;2020-03-15

4. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway;Phytotherapy Research;2019-04

5. Molecular biology as a tool for the treatment of cancer;Clinical and Experimental Medicine;2018-07-13